The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...

December has been a busy month for Alzheimer’s therapies testing new hypotheses outside of amyloid, with the latest coming Wednesday from Novo Nordisk, which said it is taking semaglutide into Phase III...

The dizzying pace of COVID-19 vaccine readouts over the last three weeks is only going to accelerate over the next five. By the end of the year, three of the four leading vaccines are likely...

Investors and bankers believe specialist-backed SPACs could become a cyclical part of biotech’s fund-raising equation with some clear advantages over traditional IPOs for the right type of company. But...

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...

Pivotal data in ulcerative colitis show two oral therapies — Jyseleca filgotinib from Gilead and Galapagos and Zeposia ozanimod from Bristol Myers Squibb — generating efficacy on par with biologics, with...

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...

This is the fifth and final article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient...

Clinical readouts for Russian COVID-19 vaccine Sputnik V indicate preexisting immunity against adenoviral vectors don’t necessarily prevent vaccine-induced immune responses against SARS-CoV-2. Sputnik...

DISEASE CATEGORY: Inflammation INDICATION: Eosinophilic esophagitis Inhibiting the extracellular serine protease KLK5 or its substrate PAR2 could treat eosinophilic esophagitis, a food antigen-driven inflammatory disease. Single-cell sequencing revealed aberrant KLK5 expression in multiple cell populations...